NCT07454330 Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
| NCT ID | NCT07454330 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2026-02-27 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2026-02-27 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate different combinations of cancer education sessions, counseling sessions, and peer support meetings developed for Chinese cancer patients and survivors. The researchers will look at whether the combinations are practical and effective, and how they impact participants' quality of life.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with cancer (any type/stage) (per EMR for MSK patients or self-report for external participants) within the last 5 years * Age ≥ 18 years (per EMR for MSK patients or self-report for external participants) Self-Report Criteria: * Of Chinese descent * Speaks Mandarin "well" or "very well" * Moderately low HRQOL (\<70 FACT-G score)4, 48 * Resides in New York or New Jersey * Agrees to participate via telehealth (video or phone) * Agrees to be audio-recorded Exclusion Criteria: Self-Report Criteria: * Per PI determination, requires a higher level of care for current passive or active suicidal ideation than current protocol is able to provide. If a participant receives a score of \> 0 on item 9 of the PHQ-9,5 they will be referred to study PI for further evaluation using the Columbia-Suicide Severity Rating Scale. They will be excluded from participation in this study if there is presence of suicidal risk, determined by affirmative response(s) on the Columbia-Suicide Severity Rating Scale (C-SSRS) * Too ill to participate determined by the question: "Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?" * Cognitive impairment (Montreal Cognitive Assessment 5 Minute - telephone version with a score \< 12) * Per consenting professional determination, unable to understand the informed consent procedure * Participation in study #14-076: Adaptation of Individual Meaning-Centered Psychotherapy for Chinese immigrant cancer patients) * Currently receiving/have received psychotherapy/counseling/peer support within the last 6 months (patients being treated solely with psychotropic medications will not be excluded if they are not receiving psychotherapy/counseling/peer support)
Contact & Investigator
Florence Lui, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07454330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07454330 currently recruiting?
Yes, NCT07454330 is actively recruiting participants. Contact the research team at luif@mskcc.org for enrollment information.
Where is the NCT07454330 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07454330 clinical trial?
NCT07454330 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Florence Lui, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 64 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.